~~<i id='87EA765FD9'><strike id='87EA765FD9'><tt id='87EA765FD9'><pre id='87EA765FD9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：leisure time 2025-10-01 02:12:25 - browse：2

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Kim Kardashian sparks debate on benefits of full

Wikipedia

leisure time

Wikipedia

entertainment

hotspot

leisure time

JustinKlee(left)andJoshuaCohenaretheco-foundersandco-CEOsofAmylyxPharmaceuticals.KayanaSzymczakforST

WSS

Change Healthcare payments predicted restored March 15

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Just how do doctors, lawmakers, and the public define abortion?

Former medical device CEO who sold dummy, plastic parts convicted of fraud

GOP presidential candidates start declaring their loyalty

Sen. Paul opposes bill to ban Chinese biotechs

focus

hotspot

Wikipedia

New air purifier tech could be key to improving indoor air quality

How to bring more disabled researchers into academia

Tori Bowie and the unacceptable rates of Black maternal death

Amylyx ALS drug fails large clinical trial

In Memoriam: Notable people who died in 2023

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Moonlake's readout produced a cash windfall. Risks remain

With psoriasis trial ahead, Alumis raises $259 million

Peter Hotez and the public health issue of online harassment

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

leisure time

Some of the ways extreme heat will change life as we know it

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Who are the detained American citizens released from prison in Iran?

NEJM study link tiny plastics in blood vessels to heart problems

TB outbreak tied to bone grafts underscores testing shortcomings

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Wikipedia

entertainment

hotspot

leisure time